Rainbow Coral today highlighted substance abuse numbers from the United States and Canada as evidence of Naltrexone’s strong growth potential; the statistics also strengthen RBCC’s plans to aggressively pursue additional partners and distribution channels to get the anti-addiction drug into as many markets as possible.
“Drug and alcohol addiction afflicts millions of North Americans struggling to free themselves from this terrible disease,” RBCC CEO Kimberly Palmer stated in the news release. “The stats don’t paint a pretty picture regarding addiction, however they do represent a window for companies like ours to deliver treatments that will change lives for the better. That’s rewarding from a personal standpoint, and offers an opportunity to build a revenue stream to reward our investors on the business side.”
Wealthy and developed countries like the U.S. and Canada have the world’s highest rates of substance abuse. According to a 2013 survey, 9.4 percent of Americans have used illicit drugs in the past month, up from 8.3 percent in 2002, while approximately 14 million Americans, 7.4 percent of the population, meet the diagnostic criteria for alcoholism. Meanwhile, about 11 percent of Canadians are afflicted with alcohol or drug addiction.
Substance at this level abuse costs U.S. taxpayers USD $700 billion per year for treatment services, employing law enforcement and related equipment. Canadian taxpayers face a C$22.8 billion tab each year to the disease.
RBCC says it is nearing agreements with a Canadian medical group that utilizes Naltrexone to treat substance abuse, as well as with another company to distribute Naltrexone in Canada.
For more information visit www.rainbowsciences.com
